March 30, 2011
EXTON, Pa.–(BUSINESS WIRE)–Physician trial and market share of Novartis’ Gilenya, the first oral disease modifying agent (DMA) for the treatment of multiple sclerosis (MS), have both increased significantly over the past quarter, according to a recent report by BioTrends. Despite uptake, neurologists report dissatisfaction with Novartis’ company support – an attribute that seems to have more impact on neurologists’ choice of DMA than they state. Use of Extavia, Novartis’s other DMA, has stabilized just over a year after launch with no anticipated changes in prescribing over the next six months. Gilenya share, on the other hand, is anticipated to increase substantially although safety concerns remain a primary obstacle for the newest DMA. The impact of Gilenya uptake is expected to be split across shares of Biogen Idec’s Avonex, Bayer’s Betaseron, Teva’s Copaxone and Pfizer/EMD Serono’s Rebif. While neurologists currently state an overall preference for Tysabri, long term safety concerns continue to hold them back from prescribing more of the brand — thus, the commercial availability of a JC antibody assay, which could help identify appropriate patients, is perceived as a possible game changer for Tysabri.
Neurologists continue to report a high unmet need for products with neuroprotective effects and significant impact on disability progression. Among the seven therapies in development that were profiled in the research, interest was highest for Teva’s laquinimod and Biogen Idec’s BG-12. Interestingly, much of the recent surge in interest in BG-12 is being driven by Gilenya early adopters.
One year post-launch, most neurologists have prescribed Acorda’s Ampyra (dalfampridine). With greater familiarity and usage, a clearer picture is emerging about the average discontinuation rate and where the product may have room for growth. On the other hand, trial, usage, and familiarity of Avanir’s Nuedexta, a recently launched agent for the treatment of pseudobulbar affect, remains limited following just weeks of commercial availability. While awareness of the four surveyed MS-related symptomatic products in development is low, neurologists report moderate levels of interest in the products and believe Otsuka’s Sativex, an agent for the treatment of spasticity, would provide the greatest clinical value to their practice.
****************************************************************
Remain CURRENT with Multiple Sclerosis information
when registered at the MS Views and News website
.
***************************************************************************************
.
“Providing You with ‘MS Views and News’, is what we do“
***************************************************************************************
.
Disclaimer: ‘MS Views and News’ (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
.
****************************************************************
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews